Endpoints News7 小时
No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al
Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the ...
Endpoints News7 小时
Tre­vi’s mid-stage chron­ic cough da­ta meet ‘home run’ sce­nario, stock soars
Trevi's Haduvio reduces chronic cough by 57% vs placebo in Phase 2a trial, surpassing expectations. Stock rises 40%.